Neuro Bo Pharmaceuticals, Inc. NRBO
We take great care to ensure that the data presented and summarized in this overview for NeuroBo Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NRBO
Top Purchases
Top Sells
About NRBO
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Insider Transactions at NRBO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Michael Salsbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+38.12%
|
-
|
|
Jun 30
2025
|
Andrew I Koven Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+38.12%
|
-
|
|
Jun 30
2025
|
D Gordon Strickland Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+38.12%
|
-
|
|
Jun 30
2025
|
James Patrick Tursi Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+43.06%
|
-
|
|
Jun 30
2025
|
Jason L Groves Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+38.12%
|
-
|
|
Jun 30
2025
|
Mark A Glickman Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,147
+42.63%
|
-
|
|
Jun 04
2025
|
Marshall H Woodworth Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
14,200
+24.28%
|
$0
$0.7 P/Share
|
|
May 08
2025
|
Dong A St Co., LTD |
BUY
Open market or private purchase
|
Direct |
4,647,887
+31.74%
|
$0
$0.71 P/Share
|
|
Mar 01
2025
|
Hyung Heon Kim CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,795
-4.38%
|
$2,795
$1.46 P/Share
|
|
Mar 01
2025
|
Marshall H Woodworth Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,417
-10.2%
|
$3,417
$1.46 P/Share
|
|
Nov 30
2024
|
Hyung Heon Kim CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,867
-4.3%
|
$5,734
$2.55 P/Share
|
|
Sep 12
2024
|
Dong A St Co., LTD |
SELL
Open market or private sale
|
Direct |
407
-0.01%
|
$1,221
$3.75 P/Share
|
|
Aug 11
2024
|
Hyung Heon Kim CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
11,467
-14.68%
|
$34,401
$3.6 P/Share
|
|
Jun 23
2024
|
Dong A St Co., LTD |
BUY
Open market or private purchase
|
Direct |
2,544,530
+32.24%
|
$7,633,590
$3.13 P/Share
|
|
Jun 07
2024
|
D Gordon Strickland Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+22.35%
|
-
|
|
Jun 07
2024
|
Mark A Glickman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+34.15%
|
-
|
|
Jun 07
2024
|
Andrew I Koven Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+22.35%
|
-
|
|
Jun 07
2024
|
Jason L Groves Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+22.35%
|
-
|
|
Jun 07
2024
|
Michael Salsbury Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+22.35%
|
-
|
|
Jun 07
2024
|
James Patrick Tursi Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,051
+35.76%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 169K shares |
|---|---|
| Open market or private purchase | 4.66M shares |
| Payment of exercise price or tax liability | 20.5K shares |
|---|---|
| Open market or private sale | 407 shares |